The Therapeutic Potential of Cannabis and Cannabinoids.

Grotenhermen Franjo, Müller-Vahl Kirsten
Deutsches Ärzteblatt International, 2012

Abstract

Background

Cannabis-based medications have been a topic of intense study since the endogenous cannabinoid system was discovered two decades ago. In 2011, for the first time, a cannabis extract was approved for clinical use in Germany.

Methods

Selective literature review.

Results

Cannabis-based medications exert their effects mainly through the activation of cannabinoid receptors (CB1 and CB2). More than 100 controlled clinical trials of cannabinoids or whole-plant preparations for various indications have been conducted since 1975. The findings of these trials have led to the approval of cannabis-based medicines (dronabinol, nabilone, and a cannabis extract [THC:CBD=1:1]) in several countries. In Germany, a cannabis extract was approved in 2011 for the treatment of moderate to severe refractory spasticity in multiple sclerosis. It is commonly used off label for the treatment of anorexia, nausea, and neuropathic pain. Patients can also apply for government permission to buy medicinal cannabis flowers for self-treatment under medical supervision. The most common side effects of cannabinoids are tiredness and dizziness (in more than 10% of patients), psychological effects, and dry mouth. Tolerance to these side effects nearly always develops within a short time. Withdrawal symptoms are hardly ever a problem in the therapeutic setting.

Conclusion

There is now clear evidence that cannabinoids are useful for the treatment of various medical conditions.

PMID:23008748
DOI:10.3238/arztebl.2012.0495
PMCID (Free PMC Article):PMC3442177
Category:Hemp Products

The best supplements with Cannabinoid in Hemp Products category:

Articles similar to "The Therapeutic Potential of Cannabis and Cannabinoids."

  • The role of Cannabinoid in Hemp Products: Cannabis-based medicines for chronic neuropathic pain in adults. ( This review is one of a series on drugs used to treat chronic neuropathic pain... The potential benefits of cannabis-based medicine (herbal cannabis, plant-derived or synthetic THC, THC/CBD oromucosal spray) in chronic neuropathic pain might be outweighed by their potential harms. The quality of evidence for pain relief outcomes reflects the exclusion of participants with a history of substance abuse and other significant comorbidities from the studies, together with their small sample sizes. )
  • The impact of Cannabinoid on Hemp Products: Cannabinoids. (Since the discovery of an endogenous cannabinoid system, research into the pharmacology and therapeutic potential of cannabinoids has steadily increased... The potential benefits of cannabis-based medicine (herbal cannabis, plant-derived or synthetic THC, THC/CBD oromucosal spray) in chronic neuropathic pain might be outweighed by their potential harms. The quality of evidence for pain relief outcomes reflects the exclusion of participants with a history of substance abuse and other significant comorbidities from the studies, together with their small sample sizes. )
  • The significance of Cannabinoid for Hemp Products: Cannabidiol, cannabinol and their combinations act as peripheral analgesics in a rat model of myofascial pain. (Objective: This study investigated whether local intramuscular injection of non-psychoactive cannabinoids, cannabidiol (CBD), cannabinol (CBN), cannabichromene (CBC) and their combinations can decrease nerve growth factor (NGF)-induced masticatory muscle sensitization in female rats... These results suggest that peripheral application of these non-psychoactive cannabinoids may provide analgesic relief for chronic muscle pain disorders such as temporomandibular disorders and fibromyalgia without central side effects. )

Previous article

Pharmacology of Cannabinoids.

Next article

Clinical Pharmacokinetics of Cannabinoids.